IkappaB kinase (IKK) catalytic subunits play a key role in cytokinemediated nuclear factor (
NF)-kappaB signaling, and a loss of
NF-kappaB function appears to inhibit
inflammation and
oncogenesis.
Manumycin A is a potent and selective
farnesyltransferase inhibitor with antitumor activity. We found that
manumycin A caused a rapid and potent inhibition of IKK activity induced by
tumor necrosis factor alpha in a number of cell types. Most unexpectedly, other classes of
farnesyltransferase inhibitors had no inhibitory effect. To identify the molecular mechanisms of
manumycin A action, cultured human HepG2
hepatoma cells were transiently transfected with various IKKalpha and IKKbeta constructs, and a striking difference in
manumycin A sensitivity was observed. Furthermore, cells expressing wild-type IKKbeta and IKKbeta mutated in the activation loop at Cys-179 exhibited covalent homotypic dimerization of IKKbeta in response to
manumycin A, whereas substitution of Cys-662 and -716 conferred protection against dimer formation. Direct inhibition of IKK activity and formation of stable IKKbeta dimers were observed in the presence of
manumycin A that could be blocked by
dithiothreitol. IKK interaction with the adaptor
protein IKKgamma/NEMO was disrupted in
manumycin A-treated cells. Most importantly, administration of
manumycin A to mice xenografted with murine B16F10
tumors caused potent IKK-suppressive effects. Thus,
manumycin A with its epoxyquinoid moieties plays an important regulatory function in IKK signaling through pathways distinct from its role as a protein farnesylation inhibitor.